Opus Genetics, Inc. (IRD) Company Overview

What does Opus Genetics do?

Opus Genetics, Inc. is a Nasdaq-listed clinical-stage ophthalmic biotechnology company developing gene therapies for inherited retinal diseases and a partnered small-molecule eye-drop franchise. Its core proposition is to deliver a functional gene to retinal cells through adeno-associated virus vectors, aiming to restore or preserve vision after one subretinal treatment. The company’s official pipeline contains seven AAV-based programs led by OPGx-LCA5 and OPGx-BEST1, plus programs targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1.

Which diseases and customers define the business?

At this stage, Opus must satisfy regulators, investigators, genetic-testing networks, retinal surgeons, payors and rare-disease communities. Patients often have severe, genetically defined degeneration with no approved disease-modifying therapy, making identification, natural-history data and trial-site execution central to the model.

How does Opus Genetics make money?

Opus currently earns license and collaboration revenue rather than meaningful self-commercialized product sales. The dominant source is its Viatris agreement covering phentolamine ophthalmic solution, including RYZUMVI for reversal of pharmacologically induced mydriasis and potential additional indications in presbyopia and low-light visual disturbances. The 2025 Form 10-K explains that revenue has consisted mainly of R&D reimbursements, prior milestone payments and smaller royalty amounts.

What are the current and future revenue engines?

The partnered PS franchise can offset cash burn and create near-term catalysts, but the larger valuation case depends on owned IRD therapies. In a DCF, collaboration revenue should be modeled as milestone- and activity-dependent, not as stable recurring revenue.

Which programs matter most to Opus Genetics?

OPGx-LCA5 leads because it has human efficacy signals, regulatory designations and a defined registrational path. OPGx-BEST1 is second because its population is larger and Cohort 1 data are imminent. Earlier programs diversify the platform, while PS adds a partnered ophthalmology option.

How does the pipeline rank by stage and strategic role?

Where is the largest disclosed patient opportunity?

What does Opus Genetics’ latest reported period show?

The latest official financial period is the quarter ended March 31, 2026. It shows a company accelerating IRD manufacturing and development while relying on financing to fund the transition. The reported net loss looks extreme, but most of the year-over-year increase came from a non-cash fair-value change in warrant liabilities rather than a comparable jump in operating cash burn.

Which numbers explain the quarter?

The Q1 2026 Form 10-Q also reported 71.4 million common shares outstanding and 7.4 million Series B preferred shares outstanding at March 31, 2026. Dilution and derivative accounting therefore remain material to per-share analysis.

What turning points created today’s Opus Genetics?

The present company combines Ocuphire Pharma’s public-company infrastructure and small-molecule ophthalmology assets with private Opus Genetics’ rare-disease gene-therapy portfolio.

1. 2018
   The public predecessor was founded as Ocuphire Pharma. Separately, private Opus was launched with Foundation Fighting Blindness support, creating a patient- and science-led IRD development model.
2. 2022
   Ocuphire signed the Viatris license for phentolamine ophthalmic solution, shifting commercialization costs to a large partner while preserving milestone and royalty economics.
3. 2023
   RYZUMVI received FDA approval, triggering a $10M milestone; the first adult participant was dosed with OPGx-LCA5, establishing the lead gene-therapy program in humans.
4. 2024
   Viatris launched RYZUMVI in April. In October, Ocuphire acquired private Opus and renamed the public company Opus Genetics, creating the current portfolio structure.
5. 2025
   Positive pediatric LCA5 data, durable adult responses and positive VEGA-3 presbyopia results expanded both the gene-therapy and partnered small-molecule narratives.
6. 2026
   A $25M private placement, up to $155M Oberland note facility, RDEP acceptance and FDA alignment on an eight-participant LCA5 Phase 3 design materially changed funding visibility and the regulatory path.

Why did the 2024 transaction matter strategically?

The October 2024 transaction filing shows that Ocuphire issued 5.24 million common shares plus Series A preferred stock convertible into roughly 14.15 million common shares to acquire private Opus. Economically, the deal transformed the company from a small-molecule ophthalmology developer into an IRD gene-therapy platform while retaining the Viatris relationship. That created more upside, but also increased program complexity, share issuance and financing needs.

What gives Opus Genetics a competitive advantage?

Opus does not have a traditional scale moat. Its potential advantage combines disease selection, specialized science, clinical proof, regulatory access and patient-network relationships. Its stated goal of an efficient path to the clinic matters because ultra-rare diseases punish slow enrollment and unfocused development.

Who are the relevant competitors?

How financially strong is Opus Genetics?

Opus is better funded than at year-end 2025 but is not self-sustaining. Cash was $45.1M on December 31, 2025; a February private placement raised $25M gross, and the April agreement added a $35M initial debt tranche plus a $5M equity investment. Management projected runway into 2029, subject to spending, milestones and conditional debt access.

What does the balance sheet imply?

Which cash-flow measure matters most?

Operating cash use is more informative for liquidity than reported net loss, while clinical spending, manufacturing, debt service and dilution remain central to long-run value. The April 2026 financing announcement stated approximately $100M of cash and runway into 2029; the underlying structure is described in the company’s official financing release.

Who owns Opus Genetics stock, and why does it matter?

Ownership is concentrated enough to matter but not dominated by a founder with majority voting control. The latest proxy used 71.15 million common shares outstanding as of March 5, 2026. Several specialist healthcare and event-driven investors approached the 9.99% beneficial-ownership threshold, while the Foundation Fighting Blindness Retinal Degeneration Fund held a strategically meaningful stake.

What does governance signal?

The 2026 proxy statement also proposed increasing authorized common shares from 125 million to 250 million, an important governance and financing signal. For a development-stage biotech, authorized share capacity can enable acquisitions, equity compensation and future fundraising, but it also creates dilution capacity. Investors therefore need to track both scientific progress and the fully diluted share count.

What opportunities could change Opus Genetics’ outlook?

The largest opportunity is that LCA5 success validates a repeatable model for other retinal diseases. July 2026 FDA alignment allows an eight-participant Phase 3 study, a six-month natural-history run-in and a potential BLA based on the six-month endpoint, with 12-month durability submitted during review.

Which milestones deserve the most attention?

The FDA-aligned LCA5 design is detailed in the company’s July 6, 2026 program update. The BEST1 timing and five-participant Cohort 1 composition are set out in the July 9, 2026 BEST1 release.

What risks could weaken the Opus Genetics story?

The risk profile is concentrated and interdependent. A small trial may be appropriate for an ultra-rare disease, yet one participant, measurement issue or manufacturing delay can materially affect the dataset. Formal risk factors emphasize clinical failure, regulation, third-party manufacturing, intellectual property, financing and commercialization.

Which risk is most material to financial value?

Clinical and regulatory risk dominates because it affects every later cash-flow assumption. If LCA5 efficacy is not replicated, the perceived probability of success for the broader platform may also fall; positive LCA5 and BEST1 data could do the opposite. A sum-of-the-parts model should therefore link program probabilities.

Why does Opus Genetics matter for valuation?

A single-stage DCF is poorly suited to Opus because current revenue does not represent the owned pipeline. A better model separates the Viatris-linked PS franchise from each gene-therapy program, assigns stage-adjusted probabilities, models launch timing and penetration, and subtracts R&D, G&A, debt and dilution.

Which variables drive intrinsic value?

For LCA5, distinguish the prevalent pool from annual incident cases and avoid assuming immediate access to all estimated patients. BEST1 and later programs need their own probabilities until human data support platform transfer. PS revenue should follow contract mechanics, milestones and royalties.

The practical valuation question is how much risk each clinical or regulatory fact removes from future cash flows. The company’s ARVO 2026 data update is relevant because it reported more than 30-fold cone-sensitivity improvement in pediatric LCA5 participants, up to a 12-letter visual-acuity gain in an early BEST1 participant and a roughly 23% reduction in central subfield thickness.

What is the key takeaway from Opus Genetics analysis?

Opus Genetics is important because it combines a lead ultra-rare gene therapy with a broader retinal platform, a partnered late-stage small-molecule franchise and newly extended financing capacity. The strongest evidence is concentrated in OPGx-LCA5: human functional-vision signals, rare-disease regulatory designations and a highly specific Phase 3 path. The most important next test is whether that evidence can be replicated in a registrational setting and translated to BEST1 and the earlier pipeline.